Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SCPX

Scorpius Holdings Inc.

May 10 • 04:00PM ET

0.1766

Dollar change +0.0008
Percentage change 0.44	%

Healthcare • Biotechnology • USA • AMEX

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.74	Insider Own	11.43%	Shs Outstand	36.03M	Perf Week	-5.02%
Market Cap	6.36M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	31.91M	Perf Month	10.35%
Income	-45.22M	PEG	-	EPS next Q	-	Inst Own	5.38%	Short Float	0.78%	Perf Quarter	-50.84%
Sales	6.99M	P/S	0.91	EPS this Y	-	Inst Trans	-22.62%	Short Ratio	0.37	Perf Half Y	-62.19%
Book/sh	1.20	P/B	0.15	EPS next Y	-	ROA	-44.80%	Short Interest	0.25M	Perf Year	-74.34%
Cash/sh	0.07	P/C	2.66	EPS next 5Y	-	ROE	-81.57%	52W Range	0.14 - 0.88	Perf YTD	-59.90%
Dividend Est.	-	P/FCF	-	EPS past 5Y	22.72%	ROI	-102.74%	52W High	-80.05%	Beta	-0.07
Dividend TTM	-	Quick Ratio	0.47	Sales past 5Y	325.62%	Gross Margin	-59.25%	52W Low	21.77%	ATR (14)	0.02
Dividend Ex-Date	-	Current Ratio	0.47	EPS Y/Y TTM	-2.40%	Oper. Margin	-639.57%	RSI (14)	48.73	Volatility	10.77% 9.99%
Employees	84	Debt/Eq	0.45	Sales Y/Y TTM	9.58%	Profit Margin	-646.44%	Recom	1.00	Target Price	8.00
Option/Short	Yes / Yes	LT Debt/Eq	0.40	EPS Q/Q	56.43%	Payout	-	Rel Volume	0.23	Prev Close	0.18
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	5966.34%	Earnings	Apr 29 BMO	Avg Volume	673.24K	Price	0.18
SMA20	3.05%	SMA50	-4.51%	SMA200	-54.73%	Trades		Volume	154,374	Change	0.44%

May-07-24 08:30AM	Scorpius Holdings Appoints New VP of Business Development Shari Udoff-McDonald (GlobeNewswire) -5.33%
Apr-29-24 08:00AM	Scorpius Holdings Provides 2023 Year-End Business Update; Reports 570% Sequential Increase in Revenue for the Fourth Quarter of 2023 (GlobeNewswire) +24.26%
Apr-23-24 05:27AM	Scorpius Holdings Gets Non-Compliance Notice From NYSE American (MT Newswires)
Apr-22-24 05:00PM	Scorpius Holdings Announces Receipt of Filing Delinquency Notification (GlobeNewswire)
Mar-19-24 08:30AM	Scorpius Holdings Awarded Contract in Excess of $1 Million with NIH-Funded Researcher at a Major University (GlobeNewswire)
08:30AM	Loading…
Mar-14-24 08:30AM	Scorpius Holdings Accepted as a Member of the US Governments BioMaP-Consortium (GlobeNewswire)
Mar-12-24 05:00PM	Scorpius Holdings, Inc. Announces Closing of Public Offering (GlobeNewswire)
Mar-08-24 12:20AM	Scorpius Holdings, Inc. Announces Pricing of Public Offering (GlobeNewswire) -51.47%
Mar-07-24 04:18PM	Scorpius Holdings, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire) +8.59%
08:30AM	Scorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023 (GlobeNewswire)
Feb-06-24 08:00AM	NightHawk Biosciences Completes Name Change to Scorpius Holdings; Trading to Commence Under SCPX Effective at the Market Open Today (GlobeNewswire) -7.71%
Feb-01-24 08:00AM	NightHawks Scorpius BioManufacturing Subsidiary Announces the Promotion of Joe Payne to President and Chief Operating Officer (GlobeNewswire)
Jan-30-24 08:00AM	NightHawk Receives Proceeds of $3.25 Million in Connection with Sale of Non-Core Intellectual Property and Issuance of a Low Interest Bearing Note (GlobeNewswire)
Jan-25-24 08:30AM	NightHawks Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical Program (GlobeNewswire) +10.54%
Jan-16-24 08:30AM	NightHawks Scorpius BioManufacturing Subsidiary Commences Work on Preclinical Program for New Client (GlobeNewswire)
08:30AM	Loading…
Jan-08-24 08:30AM	NightHawk Biosciences Announces Planned Name Change to Scorpius Holdings, Reflecting Successful Transition to a Large Molecule Biomanufacturing CDMO (GlobeNewswire)
Jan-03-24 08:30AM	NightHawk Biosciences Commences Work on Multi-Million-Dollar Development and Manufacturing Agreement For a Leading National University (GlobeNewswire)
Dec-21-23 08:30AM	NightHawk Biosciences Announces Completion of Demonstration Run for a Top-Tier NIH and DTRA Funded Research University (GlobeNewswire) +12.30%
Dec-18-23 08:30AM	NightHawk Biosciences Announces Major Milestone with Completion of Manufacturing Run for a Premier U.S.-Based Biopharmaceutical Company (GlobeNewswire) +18.22%
Dec-12-23 08:30AM	NightHawk Biosciences Announces Strategic Shift into a Pure-Play Large Molecule Biomanufacturing CDMO to Capitalize on Rapid Growth in Sales Pipeline along with Divestiture of Non-Core Assets (GlobeNewswire)
Nov-20-23 04:05PM	NightHawk Biosciences Provides Q3 2023 Business Update (GlobeNewswire)
Oct-09-23 08:26AM	NHWK: 2Q:23 Results (Zacks) -5.89%
Aug-24-23 08:24AM	Morrisville CEO wants to acquire his company's subsidiary for $45M+ (American City Business Journals)
08:24AM	Morrisville CEO pitches to buy his company's subsidiary for $45M+ (American City Business Journals)
Aug-14-23 04:05PM	NightHawk Biosciences Provides Q2 2023 Business Update (GlobeNewswire)
May-19-23 10:46AM	NHWK: First Scorpius Revenues (Zacks Small Cap Research)
May-15-23 04:05PM	NightHawk Biosciences Provides Q1 2023 Business Update (GlobeNewswire)
Apr-11-23 08:23AM	NHWK: ANTHIM Sales Boost Revenues (Zacks Small Cap Research) -6.10%
Mar-31-23 04:05PM	NightHawk Biosciences Provides 2022 Year End Business Update (GlobeNewswire)
Dec-12-22 09:02AM	NHWK: Shifting Focus to Biomanufacturing (Zacks Small Cap Research)
04:01PM	Loading…
Nov-14-22 04:01PM	NightHawk Biosciences Provides Third Quarter 2022 Business Update (GlobeNewswire)
Oct-21-22 08:00AM	Nighthawk Biosciences Scorpion Subsidiary Announces Grand Opening of its San Antonio Facility (GlobeNewswire)
Aug-23-22 07:30AM	NightHawk Biosciences Announces Buildout of Advanced Biosafety Level 2 (BSL-2) Laboratory (GlobeNewswire) -14.57%
Aug-17-22 10:55AM	NHWK: Scorpion Grand Opening 3Q:22 (Zacks Small Cap Research)
10:55AM	NHWK: BLA Filing for ALS Treatment Upcoming (Zacks Small Cap Research)
Aug-10-22 04:05PM	NightHawk Biosciences Provides Second Quarter 2022 Business Update (GlobeNewswire)
Jun-13-22 08:00AM	NightHawk Biosciences Appoints Stephan Kutzer, Ph.D. as Interim Chief Executive Officer of Scorpion Biological Services (GlobeNewswire) -6.18%
May-18-22 12:48PM	NHWK: Name Change and New Facility (Zacks Small Cap Research) -7.35%
May-16-22 04:44PM	NightHawk Biosciences Provides First Quarter 2022 Business Update (GlobeNewswire) +14.51%
May-10-22 08:00AM	NightHawk Biosciences to Present at the 4th Annual Treg Directed Therapies Summit on PTX-35 (GlobeNewswire) -8.29%

Scorpius Holdings, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SCPX

Scorpius Holdings Inc.

Upgrade your FINVIZ experience